+1 8448850006
Latest Pharma & Healthcare Insights

MEAgate to distribute Alimera Sciences' diabetes drug Iluvien in Middle East

Company Report

 A pharm company Alimera Sciences, Inc. announced that the company’s subsidiary Alimera Sciences B.V. has undergone an agreement with MEAgate International FZLLC (MEAgate) which is headquartered in the United Arab Emirates (UAE). The agreement has been made to distribute Almiras Sciences diabetes drug Iluvien across Middle East and the countries which are involved in agreement includes Kuwait, Lebanon, Oman, Bahrain, Egypt, Iraq, Jordan, Qatar, Saudi Arabia, UAE, and Yemen. MEAgate has 35 years of experience in pharmaceutical and medical device in Middle East and involves tenure with Merck, Medtronic and GE Healthcare. 

Dream Samir, partner and CEO of MEAgate  stated that "The Middle East market holds great opportunity with a population that exceeds 200 million people, a high rate of diabetes and developing healthcare systems. We believe Iluvien will be a welcome addition for those with diabetic macular edema in the region. MEAgate will ensure high scientific and compliant standards while managing a network of carefully chosen country distributors for Alimera."

Phase 3 clinical study of Illuvien showed the primary endpoint as improvement in vision of 15 letters or more at 24 months wherein the most frequently reported adverse drug reactions involved increased ocular pressure and cataract development.

MEAgate will be opening the scientific office in the Middle East for sales, marketing, regulatory and medical affairs of Alimera. MEAgate will have altogether 5 medical science liaisons wherein 2 will be in Egypt, 2 in Saudi Arabia and 1 in the Gulf Cooperation Council countries which are expected to begin in Egypt, UAE, Saudi Arabia and Lebanon in 2016 to support Named Patient Sales which is an early access program where health authorities select institutions so as to provide innovative medications even when the products are process of approval and registration. 

Dan Myers, president and CEO, Alimera stated that "MEAgate is an excellent partner for Alimera to increase the availability of Iluvien. Their management team knows how to navigate the variable economic and healthcare systems across countries in the region, which should provide us with a terrific opportunity to make Iluvien a market leader in the Middle East."

According to Pharmaion, pharma and healthcare consultants, Iluvien has already received approval to treat diabetic macular edema (DME) and found to be effective in patients who were not responsive to corticosteroids. The approval of drug sales across middle east will help in creating a new and effective treatment option for the patients.


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News